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Human epidermal growth factor receptor 2 (HER2) immunoreactivity: speciﬁcity of three
pharmacodiagnostic antibodies
Aims: The availability of speciﬁc antibody-based test
systems is essential to testing of HER2 protein expres-
sion. Here, we mapped epitopes recognized by three
pharmacodiagnostic HER2 antibodies and investigated
their speciﬁcity towards peptides and fusion proteins
homologous to the intracellular domains of HER1, HER2,
HER3 and HER4. The investigated antibodies were
PATHWAY
  HER2 (clone 4B5; Ventana Medical Systems
Inc., Tucson, AZ, USA), HercepTest  (Dako Denmark
A ⁄ S, Glostrup, Denmark), and Oracle
  HER2 (clone
CB11; Leica Microsystems GmbH, Wetzlar, Germany).
Methods and results: Epitopes were mapped using the
alanine scanning method. Speciﬁcity was investigated in
immunohistochemical stainings, competitive enzyme-
linked immunosorbent assay (ELISA) and immunoblot-
ting. All three antibodies reacted with HER2 proteins and
peptides in immunohistochemical stainings, ELISA and
immunoblotting. PATHWAY
  HER2 also stained HER4-
expressing cells, reacted with HER4 peptide in ELISA and
detected HER4 fusion protein in an immunoblot. Oracle
 
HER2 weakly detected HER4 in immunohistochemical
stainings, whereas the HercepTest  antibody showed no
cross-reactivity with other HER proteins.
Conclusion: Our study shows that the PATHWAY
 
HER2 antibody can bind HER4 peptides and fusion
proteins in three different experimental settings. This
should be investigated further to determine whether
binding of HER4 also occurs in tissue samples and if
such binding would have implications for therapy
decisions for breast cancer patients.
Keywords: antibody speciﬁcity, HER2 protein, immunohistochemistry
Abbreviations: CHO, Chinese hamster ovary; EGFR, epidermal growth factor receptor; ELISA, enzyme-linked
immunosorbent assay; FFPE, formalin-ﬁxed, parafﬁn-embedded; GST, glutathione S-transferase; HER2, human
epidermal growth factor receptor 2; PCR, polymerase chain reaction
Introduction
Human epidermal growth factor receptor 2 (HER2)
belongs to the family of epidermal growth factor
receptors (EGFRs). This family consists of four mem-
bers; epidermal growth factor receptor (EGFR), HER1,
HER2, HER3 and HER4. HER proteins show extensive
sequence homology and through formation of homo-
and heterodimers induce complex intracellular signal-
ling (reviewed in Yarden and Sliwkowski
1).
HER2 protein is overexpressed in approximately 20–
25% of breast tumours and overexpression correlates
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2,3 Overexpression
of HER2 protein and ⁄ or ampliﬁcation of the HER2 gene
are associated with a poor outcome in breast cancer
patients.
4,5 Expression of HER1, HER3 and HER4 in
breast tumour tissue has also been demonstrated;
however, the reported fraction of tumours expressing
or overexpressing these HER proteins vary.
6–8 Expres-
sion of HER1 and HER3 has been linked with a poor
outcome and increased cell proliferation in breast
cancer, whereas HER4 expression has been associated
with reduced mortality and decreased proliferation.
6–8
Breast cancer patients whose tumours overexpress
HER2 and ⁄ or show ampliﬁcation of the HER2 gene are
candidates for HER2-targeted therapy with trast-
uzumab
9 or other HER2-targeting drugs. Testing of
HER2 protein expression by immunohistochemical
staining (IHC) requires speciﬁc antibodies; however,
testing inaccuracy and discrepancy among results from
studies employing different antibodies has been a major
issue.
3,10–13 Accordingly, continued investigation of
such tests is required.
In this work we studied three antibodies, which are
components of different IHC-based HER2 tests. We
mapped their epitopes in the HER2 protein and
subsequently studied the antibodies’ speciﬁcity to-
wards the relevant part of HER2 and homologous
parts of HER1, HER3 and HER4. This was conducted
in three different immunochemical settings: ﬁrst,
antibody speciﬁcity was investigated by staining of
formalin-ﬁxed, parafﬁn-embedded (FFPE) Chinese
hamster ovary (CHO) cells transfected with the
intracellular domain of HER 1–4, respectively. Sec-
ondly, the ability of the antibodies to bind HER1,
HER2 and HER4 peptides was tested in a competitive
enzyme-linked immunosorbent assay (ELISA). Thirdly,
immunoblotting of Escherichia coli-expressed fusion
proteins consisting of glutathione S-transferase (GST)
and part of the intracellular domain of HER1, HER2,
HER3 or HER4, respectively, was performed. As all
three investigated antibodies are used for determina-
tion of HER2 status as an aid in the assessment of
patients for whom HER2-targeted therapy is being
considered, we expected them to show speciﬁcity
towards HER2. Hence, our hypothesis states that
these antibodies are speciﬁc.
Our data conﬁrm that all three investigated antibod-
ies react with HER2 protein. However, here we also
show that one antibody cross-reacts with HER4 protein
and peptide in both IHC staining of HER4-transfected
cells, in competitive ELISA and in immunoblotting. The
speciﬁcity of this antibody needs further investigation
and the potential clinical implications of cross-reactiv-
ity should be addressed.
Materials and methods
antibodies
The investigated antibodies are components of different
IHC-based HER2 tests: PATHWAY
  HER2 (clone 4B5;
Ventana Medical Systems Inc., Tucson, AZ, USA),
HercepTest  (Dako Denmark A ⁄ S, Glostrup, Den-
mark) and Oracle
  HER2 (clone CB11; Leica Microsys-
tems GmbH, Wetzlar, Germany). The PATHWAY
 
HER2 and HercepTest  antibodies were applied in all
experiments, whereas two variants of the CB11 anti-
body were available: for IHC the antibody recom-
mended for staining with the Bond-III was used
(Oracle
  HER2, clone CB11; Leica Microsystems
GmbH), and for ELISA and immunoblotting experi-
ments the corresponding CB11 antibody concentrate
was employed (Novocastra NCL-CB11; Leica Microsys-
tems A ⁄ S, Ballerup, Denmark). All three antibodies are
reported to bind the intracellular region of HER2 near
the C-terminal end of the protein (HercepTest  pack-
age insert; Powell et al.
10; Corbett et al.
14).
epitope mapping and alignment of her
proteins
The binding sequence in HER2 for each of the three
antibodies was delineated using the alanine scanning
method.
15 Brieﬂy, peptides are synthesized substituting
an alanine at each position in the peptide, and binding
of each antibody to the synthetic peptides is investi-
gated using ELISA (Pepscan Presto BV, Lelystad, the
Netherlands).
The region in HER2 harbouring epitopes recognized
by the antibodies was aligned with the corresponding
regions in HER1, HER3 and HER4.
immunohistochemistry
Formalin-ﬁxed, parafﬁn-embedded cell blocks were
made containing CHO K1 cells transfected with the
intracellular domain of HER1, HER2, HER3 or HER4,
respectively. For construction of plasmids polymerase
chain reaction (PCR) was performed using cDNA from
human cell lines or commercially available RNA [for
HER1 the A431 cell line; for HER2 the SK-BR-3 cell
line; for HER3 the MCF-7 cell line; and for HER4
human muscle mRNA (Invitrogen A ⁄ S, Taastrup,
Denmark)]. Primers were selected to amplify the coding
sequences of the proteins’ intracellular domains. PCR
products were puriﬁed using the MinElute PCR puriﬁ-
cation kit (Qiagen, Copenhagen, Denmark); sequences
were veriﬁed by sequencing (Euroﬁns MWG Operon,
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Invitrogen A ⁄ S) directs the protein into the membrane
of the host cell line CHO K1 and harbours a speciﬁc tag
for determination of transfection efﬁciency. The puriﬁed
PCR products were cloned into this vector, transformed
into TOP10-competent E. coli cells, and plasmids were
puriﬁed by an EndoFree Plasmid Maxi Kit (Qiagen).
CHO K1 cells were transfected with one of the four
plasmids, respectively, by incubation with Lipofecta-
mine  LTX (Invitrogen A ⁄ S) for 26 h. Cells were
harvested with trypsin, washed in phosphate-buffered
saline (PBS) and cell pellets were mixed with 2% agar
and transferred to a plastic pipette for construction of
cell straws. Cell straws were ﬁxated in formalin [10%
formalin in Tris-buffered saline (TBS)] for 24 h. The
ﬁxated cells were dehydrated in a tissue processor;
2 · 1 h in 70% alcohol, 2 · 1 h in 96% alcohol,
2 · 1 h in 99% alcohol and 2 · 1 h in xylen. Finally,
cells were embedded in parafﬁn overnight.
Immunohistochemical stainings were performed on
automated IHC platforms according to the manufactur-
ers’ instructions (PATHWAY
  HER2 on BenchMark
ULTRA, HercepTest  on Dako Autostainer and Oracle
 
HER2onBond-III).Eachcellpelletwasincludedtwiceon
each slide and two separate slides were stained per run.
Each run was repeated on three independent occasions.
elisa
Synthetic peptides (PolyPeptide Group, Strasbourg,
France) were used in ELISA experiments (Figure 1B).
The HER2 peptide corresponded to the part of the
intracellular domain containing the epitopes (amino
acids 1242–1254). Peptides representing HER1 (amino
acids1191–1203),HER3(aminoacids1322–1334)and
HER4 (amino acids 1278–1290) were synthesized to
covertheregionhomologoustoHER2.TheHER3peptide
couldnotbeemployedinELISAduetounspeciﬁcbinding
of the peptide to the microtitre plate. Accordingly, the
ability of the HER3 peptide to compete with antibody
binding to HER2 in ELISA was not investigated.
For the competitive ELISA, microtitre plates were
coated overnight (4 C) with HER2 peptide (1 lg ⁄ ml in
carbonate buffer, pH 9.6). Next, plates were incubated
(1 h, 30 C) with HER2 antibody together with increas-
ing concentrations of HER1, HER2 or HER4 peptides
(concentration range, 0–10 lg ⁄ ml). After washing,
remaining antibody was detected using relevant sec-
ondary alkaline phosphatase-conjugated antibodies
(Dako A ⁄ S) and incubation with p-nitrophenyl phos-
phate substrate. After 1 h, colour development was
quantiﬁed at 405 nm in an automatic plate reader
(BioTek Instruments Inc., Winooski, VT, USA). Optical
density (OD) values were normalized to control wells
with coating peptide and antibody only (100% signal).
Prior to performing the ELISA, determination of
appropriate primary antibody concentrations was per-
formed by titration of the three antibodies individually
against coated antigen; the concentrations of the
antibodies were selected to give OD values approxi-
mately in the middle of the dynamic range. ELISA
experiments were performed independently three times.
immunoblotting
Protein fragments representing part of the intracellular
domain of HER1, HER2, HER3 and HER4 fused to GST
were constructed. Brieﬂy, domain-encoding sequences
were ampliﬁed using standard PCR techniques; se-
quences were veriﬁed by sequencing (Euroﬁns MWG
Operon, Ebersberg, Germany) and subcloned into the
pIVEX-GST expression vector (Roche Diagnostics A ⁄ S,
Hvidovre, Denmark) downstream of the GST gene; the
construct also includes a C-terminal hexa-histidine
afﬁnity tag. Fusion proteins were expressed in E. coli
and puriﬁed as soluble or insoluble aggregates using
nickel chelating afﬁnity chromatography puriﬁcation
techniques.TheconcentrationofGST-fusionproteinand
protein identity was evaluated using sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) Coomassie staining and anti-GST immunoblot-
ting. Equal amounts of speciﬁc proteins (GST–HER1, –
HER2,–HER3and–HER4)wereloadedontothegels;this
was conﬁrmedusinga GST-speciﬁcantibody(1:30 000;
GE Healthcare Europe GmbH, Brondby, Denmark).
Gel electrophoresis was performed using an XCell
SureLock  Mini-Cell electrophoresis system with Nu-
PAGE
  4–12% BisTris gels according to the manufac-
turer’s instructions (Invitrogen A ⁄ S), followed by
Antibody Epitope in HER2
PATHWAY® HER2 TAENPEYLGL
Herceptest™ ENPEYLGLDVP
Oracle® HER2 AENPEYL
Protein Position Amino acid residue GenBank access number
HER1 1191–1203 TAENAEYLRVAPQ X00588
HER2 1242–1254 TAENPEYLGLDVP X03363
HER3 1322 1334 AFDNPDYWHSRLF M29366
HER4 1278–1290 VAENPEYLSEFSL L07868
A
B
Figure 1. Amino acids in human epidermal growth factor receptor 2
(HER2) that constitute epitopes recognized by each antibody (A)
and alignment of part of the intracellular domains of HER1, HER2,
HER3 and HER4 (B).
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Healthcare Europe GmbH) and incubation with pri-
mary antibodies and secondary horseradish peroxidase-
conjugated antibodies. HER2 antibodies were diluted
1:3000 (PATHWAY
  HER2), 1:1000 (HercepTest )
and 1:80 000 (CB11 concentrate). Secondary antibod-
ies (Dako A ⁄ S) were diluted 1:3000. Blots were
developed using Amersham ECL Advance or ECL Plus
Western Blotting Detection Kits (GE Healthcare Europe
GmbH), according to the manufacturer’s instructions.
After development and visualization, blots were
stripped (62.5 mm Tris, 2% SDS, 0.7% b-mercaptoeth-
anol), reprobed with HER4 antibody (1:4000, OriGene
TA303501-100; Rockville, MD, USA) and developed.
Bands were visualized in an UVP Biospectrum Imaging
System; the resulting images were inverted in ImageJ
for clearer visualization. Experiments were performed
independently three times.
Results
epitope mapping and alignment of her
proteins
Figure 1A shows the result of epitope mapping and
illustrates amino acid residues in HER2 that constitute
epitopes recognized by each of the antibodies. The
antibodies bind to overlapping sequences and the
recognized epitopes share a sequence of six consecutive
amino acids (HER2 amino acids 1244–1249). The
Oracle
  HER2 antibody binds to the shortest epitope
(seven amino acid residues) compared to Herceptest 
and PATHWAY
  HER2 antibodies (epitopes of 11 and
10 amino acid residues, respectively). Figure 1B shows
the amino acid sequence in HER2 that harbours all
three epitopes and the sequences in corresponding
parts of HER1, HER3 and HER4.
A B
D C
Figure 2. PATHWAY
  human epidermal growth factor receptor 2 (HER2) immunostaining of Chinese hamster ovary (CHO) K1 cells
transfected with the intracellular domain of HER1 (A), HER2 (B), HER3 (C) or HER4 (D). A representative area is shown.
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Figures 2–4 show immunostaining of FFPE CHO K1
cells transfected with the intracellular domain of
HER1, HER2, HER3 or HER4. Transfection efﬁciency
for the applied protocol was 10–50%; this was
conﬁrmed by staining transfected cells with a tag-
speciﬁc antibody (data not shown). Figure 2 shows
cells stained with PATHWAY
  HER2; this antibody
stained HER2-transfected cells and cells transfected
with the intracellular domain of HER4. With Hercep-
Test  (Figure 3), only cells transfected with the
intracellular domain of HER2 were stained. Finally,
the Oracle
  HER2 antibody stained HER2 transfected
cells and weakly stained few HER4 transfected cells
(Figure 4). Representative areas are shown for all
immunostainings.
competitive elisa
Antibody dilution experiments showed good ELISA
performance (50% ODmax) for the PATHWAY
  HER2
antibody at 1:40 dilution, for the HercepTest  anti-
body at 1:20 dilution, and for the CB11 antibody
concentrate at 1:1600 dilution. Figure 5A shows the
result of a competitive ELISA employing the PATH-
WAY
  HER2 antibody; here, addition of HER2 and
HER4 peptides, respectively, competed with coated
HER2 peptide for antibody binding, whereas addition
of HER1 peptide did not. A similar competitive ELISA
(Figure 5B) showed that only added HER2, and not
HER1 or HER4, competed with coated peptide for the
HercepTest  antibody’s binding. Similarly, only added
HER2 competed with coated HER2 peptide for binding
to the CB11 antibody (Figure 5C).
A B
D C
Figure 3. HercepTest  human epidermal growth factor receptor 2 (HER2) immunostaining of Chinese hamster ovary (CHO) K1 cells transfected
with the intracellular domain of HER1 (A), HER2 (B), HER3 (C) or HER4 (D). A representative area is shown.
Speciﬁcity of HER2 antibodies 979
  2011 Blackwell Publishing Ltd, Histopathology, 59, 975–983.immunoblotting
Figures 6A–D and 7 show the results of immunoblot-
ting experiments. The PATHWAY
  HER2 antibody
detected both GST–HER2 and GST–HER4 (Figure 6A);
the identity of GST–HER4 was conﬁrmed by stripping
and reprobing the blot using a HER4 antibody (Fig-
ure 7). HercepTest  (Figure 6B) and CB11 (Figure 6C)
antibodies did not cross-react with GST–HER4,
although vague staining of GST–HER4 could be
achieved with the CB11 antibody after extended
exposure time. The control blot (Figure 6D) shows that
equal amounts of GST-fusion proteins were loaded.
Discussion
In this study we investigated the speciﬁcity of three
pharmacodiagnostic HER2 antibodies towards fusion
proteins and synthetic peptides homologous to pro-
teins of the HER family. All three antibodies reacted
with HER2 proteins and peptides. One antibody
(PATHWAY
  HER2) did not bind HER1 or HER3,
but clearly cross-reacted with HER4 proteins and
peptides in all our experiments: in IHC, HER4-
transfected cells were intensely stained with the
PATHWAY
  HER2 antibody; a synthetic peptide
corresponding to part of the HER4 intracellular
domain competed with antibody binding to HER2 in
ELISA; and a GST–HER4 band was detected in
immunoblotting. Thus, this antibody reacted with
HER4 across three different experimental techniques.
The second antibody (from HercepTest ) did not
cross-react with HER1, HER3 or HER4, while the third
antibody (Oracle
  HER2) weakly stained a small
number of cells transfected with the intracellular
domain of HER4 and was able to detect a GST–HER4
A
C D
B
Figure 4. Oracle
  human epidermal growth factor receptor 2 (HER2) immunostaining of Chinese hamster ovary (CHO) K1 cells transfected
with the intracellular domain of HER1 (A), HER2 (B), HER3 (C) or HER4 (D). A representative area is shown.
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HER4 synthetic peptide did not show competition with
binding of the CB11 antibody to HER2 in ELISA.
Our immunohistochemical stainings were performed
strictly according to the manufacturers’ instructions on
the recommended equipment; hence the observed
reactivity to HER2, and for the PATHWAY
  HER2
antibody also to HER4, can be expected to occur when
using these kits in a routine setting. Our ELISA
included positive as well as negative controls for
comparison and monitoring of assay performance.
Immunoblots were performed similarly for all antibod-
ies and the identity of the HER4 protein to which the
PATHWAY
  HER2 antibody bound was conﬁrmed by
stripping and reprobing the membrane.
The HER2 protein shows sequence homology to
other HER family members in the C-terminal part
(Figure 1B). HER1 and HER4 sequences show most
overlap with HER2 in this region of the protein; the
alignment of intracellular regions of the proteins
reveals that over a sequence of seven amino acids,
HER2 and HER4 are 100% homologous whereas HER2
and HER1 proteins also share wide sequence homology
but only an uninterrupted, homologous sequence of
four amino acids. HER3 shows the least homology to
HER2; alignment of HER2 and HER3 shows homology
at three positions (HER3 residues 1325, 1326 and
1328). Based on these alignments and on the epitope
mapping, extensive cross-reactivity is theoretically
possible as all three antibodies recognize partly over-
lapping epitopes, and HER2 has sequence homology
with both HER1 and HER4. However, we only consis-
tently found cross-reactivity for the PATHWAY
  HER2
antibody and only to HER4. Our results are not in
keeping with previously published data suggesting that
the PATHWAY
  HER2 antibody does not cross-react
with other members of the HER family:
10 in an
immunoblot of various cell lysates, Powell et al. showed
that the PATHWAY
  HER2 antibody stained only
HER2 and not HER1, HER3 or HER4. This report,
however, neither demonstrated how much HER protein
was loaded nor adjusted loading to ensure equal
amounts of HER1, HER2, HER3 and HER4 protein. In
the present study, we loaded equal amounts of HER–
GST fusion proteins (Figure 6D) and also conﬁrmed the
identity of the cross-reacting protein with a HER4
speciﬁc antibody (Figure 7). We observed cross-reac-
tivity for the PATHWAY
  HER2 antibody across three
different experimental platforms and in particular, we
found staining of HER4-transfected cells. The use of
FFPE-transfected cells probably reﬂects actual HER
family members’ epitopes in FFPE material. Addition-
ally, the results of the epitope mapping (Figure 1A)
demonstrated that all three antibodies recognize linear
epitopes; consequently, these are likely to be similar in
our peptides and fusion proteins and in full-length
native protein.
Weak staining of HER4-transfected cells was also
observed for the Oracle
  HER2 antibody; however, as
this staining was not intense and only present in a
small fraction of cells we speculate that it is due to
high expression levels of HER4 protein in some
transfected cells, and that this may not occur in
clinical samples. The Oracle
  Bond HER2 immuno-
histochemical staining system employs afﬁnity-puriﬁed
CB11 antibody,
16 whereas the CB11 concentrate used
for ELISA and immunoblotting is not puriﬁed. How-
ever, although unpuriﬁed, the CB11 concentrate was
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Figure 5. Results of competitive enzyme-linked immunosorbent
assay (ELISA). Human epidermal growth factor receptor 1 (HER1),
HER2 and HER4 peptides were added and competition investigated
for the PATHWAY
  HER2 antibody (A), the HercepTest  anti-
body (B) and the CB11 antibody concentrate (C). The ﬁgure shows
the result of one experiment representative of three independent ones.
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immunoblots.
Our study indicates that the PATHWAY
  HER2
antibody can bind HER4 homologous protein and
peptide in three different experimental settings. How-
ever, as described, we have not detected native human
HER proteins in this study. Thus, it remains to be
shown whether staining of breast cancer tissue sections
with this particular antibody leads to detection of HER4
protein. If so, it should be investigated whether the
potential detection of HER4 protein would have any
clinical implications. It may be possible that patients
believed to be HER2-positive would receive HER2-
targeted therapy while in fact being only HER4-
positive. Similarly, HER2 low-expressing tumours
(1+) could be classiﬁed erroneously as 2+ or 3+ due
to detection of HER4 together with HER2. A study of
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Figure 6. Immunoblots of glutathione S-transferase (GST)–human epidermal growth factor receptor (HER) fusion proteins. Identical blots were
developed using the PATHWAY
  HER2 antibody (A), the HercepTest  antibody (B) and the CB11 antibody concentrate (C). D, The loading
control (anti-GST). The ﬁgure shows the result of one experiment representative of three independent ones.
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oftheblotinitiallydevelopedusingthePATHWAY
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when using the PATHWAY
  HER2 antibody than
when employing the HercepTest  antibody, although
a very high concordance between PATHWAY
  HER2
IHC and ﬂuorescence in-situ hybridization (FISH) was
found.
13 Conversely, if HER4 is expressed mainly
together with high levels of HER2, the simultaneous
detection of both proteins would have no clinical
implications in the assignment or not of HER2-targeted
therapy. Expression of HER4 protein in breast cancer
tissue has been demonstrated; however, uncertainty
about the level and extent of expression persists.
Examining only the presence or absence of staining, a
study of 191 breast cancer tissue samples revealed
HER4 protein expression in 37.2% of the samples; this
study also reported that 71% of HER2 overexpressing
cases coexpressed HER4.
7 Another group reported
HER4 protein expression in 69.5% of 220 breast
cancer tissue samples but demonstrated that HER4
was rarely coexpressed with other members of the HER
family.
6 A third study found HER4 staining in only six
of 54 (11%) breast tumours.
8 Thus, despite lack of
consistency across studies, HER4 protein is expressed in
breast cancer tissue, and two studies
6,7 suggest that
HER4 expression may indeed be present without
coexpression of HER2. Thus, a false-positive HER2
signal could be possible if using a HER2 antibody which
cross-reacts with HER4.
In conclusion, our study shows that one pharma-
codiagnostic antibody can bind HER4 protein and
peptide in IHC, ELISA and immunoblots, suggesting
that it could also bind to the intracellular domain of
HER4 in clinical breast cancer samples. It should be
investigated whether such cross-reactivity occurs in
breast cancer tissue and whether potential detection of
HER4 protein could have implications for selection of
treatment for breast cancer patients.
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